Chinese Biotech Firm Ascletis Leads Series E Round In American Pharma 3-V Biosciences

An affiliate of Hong Kong-listed Chinese biotech company Ascletis Pharma has led a US$18 million series E financing round in San Francisco-based clinical-stage pharmaceutical firm 3-V Biosciences, said Ascletis in a statement released on Monday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets